Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

VINYLPYRROLIDINE/ METHACRYLAMIDOPROPYLTRIMETHYLAMMONIUM CL

NFPA

PRODUCT USE

Synthetic polymer. Conditioning agent in permanent wave lotions, conditioning shampoos,
rinse conditioners. Film- former in styling products (lotions. glazes, gels and mousses).
Additive for improved feel in hand and body lotions, moisturising creams.

SYNONYMS

(C6-H9-N-O)x.(C9-H21-N2-O-Cl)y, (C6-H9-N-O)x.(C9-H21-N2-O-Cl)y, "[3-
(methyacryloylamino)propyl]trimethylammonium chloride polymer withN-vinyl-2-pyrrolidone",
"[3-(methyacryloylamino)propyl]trimethylammonium chloride polymer withN-vinyl-2-
pyrrolidone", "vinylpyrrolidone [3-(methacryloylamino)propyl]trimethylammonium chloride",
"vinylpyrrolidinone methacrylamide propyltrimethyl ammonium chloride", "vinylpyrrolidone/
MAPTAC copolymer", "PVP quaternised copolymer", "Agent AT-1269", "Gafquat HS-100",
polyquaternium-28

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW

RISK

Irritating to eyes, respiratory system and skin.
Toxic to aquatic organisms.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

  Although ingestion is not thought to produce harmful effects, the material may still be damaging to the health of the individual following ingestion, especially where pre-  existing organ (e.g. liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally based on doses producing mortality (death) rather than those producing morbidity (disease, ill-health). Gastrointestinal tract discomfort may produce nausea and vomiting. In an occupational setting however, ingestion of insignificant quantities is not thought to be cause for concern.  Considered an unlikely route of entry in commercial/industrial environments.  High molecular weight material; on single acute exposure would be expected to pass through gastrointestinal tract with little change / absorption. Occasionally accumulation of the solid material within the alimentary tract may result in formation of a bezoar (concretion), producing discomfort.  Concentrated solutions of many cationics may cause corrosive damage to mucous membranes and the esophagus. Nausea and vomiting (sometimes bloody) may follow ingestion. Serious exposures may produce an immediate burning sensation of the mouth, throat and abdomen with profuse salivation, ulceration of mucous membranes, signs of circulatory shock (hypotension, labored breathing, and cyanosis) and a feeling of apprehension, restlessness, confusion and weakness. Weak convulsive movements may precede central nervous system depression. Erosion, ulceration, and petechial hemorrhage may occur through the small intestine with glottic, brain and pulmonary edema. Death may result from asphyxiation due to paralysis of the muscles of respiration or cardiovascular collapse. Fatal poisoning may arise even when the only pathological signs are visceral congestion, swallowing, mild pulmonary edema or varying signs of gastrointestinal irritation. Individuals who survive a period of severe hypertension may develop kidney failure. Cloudy swelling, patchy necrosis and fatty infiltration in such visceral organs as the heart, liver and kidneys shows at death.  

EYE

  This material can cause eye irritation and damage in some persons.  

SKIN

  This material can cause inflammation of the skin oncontact in some persons.  Skin contact is not thought to have harmful health effects, however the material may still produce health damage following entry through wounds, lesions or abrasions.  

INHALED

  If inhaled, this material can irritate the throat andlungs of some persons.  Although inhalation is not thought to produce harmful effects, the material may still produce health damage, especially where pre-existing organ (e.g. liver, kidney) damage is evident. Present definitions of harmful or toxic substances are generally confined to doses producing mortality (death) rather than those producing morbidity (disease, ill-  health).  Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.  

CHRONIC HEALTH EFFECTS

  Principal routes of exposure are usually by skin contact/absorption and inhalation of generated dust.  Contact sensitisation test were performed on 110 human subjects. the  induction phase consisted of a series of 9 applications at 0.2 ml of a 5%  solution over a 3 week period, applied under an adhesive patch to an area  of the left upper back. Approximately two weeks after the end of the  induction phase, subjects were challenged with a single application (0.2  ml, 5% solution) to a virgin area of the right upper back. Sensitisation  ws assessed 24-96 hours late. No skin reactions were noted in the 104  subjects who finished the test.  Phototoxicity studies: 0.2 ml of a 5% solution of Agent AT-1269 was  applied in adhesive patches to the forearms (volar surface) of each of  10 human subjects. After 24 hours contact one arm of each subject, was  irradiated with UVA (0.22 J/cms/min for 15 minutes). No reactions were  seen in irradiated or unirradiated sites after 24 or 48 hours.  Photoallergy studies: Agent At-1269 was tested for dermal contact  photoallergy ij 29 human subjects. The induction phase consisted of a  series of 6 applications of 0.2 ml of a 5% solution of AT-1269, over a  three week period, applied under adhesive patches on the volar surface of  the forearm. Twenty-four hours after each application, arms were  irradiated with UV-A (3.33 J/cm2) and UV-B (dosage in the range 75  seconds at 90 mJ - 105 seconds at 126 mJ depending on the previously  assessed skin type). Untreated irradiated patches and treated  non-irradiated patches were used as controls.  Approximately 2 weeks after the end of the induction phase subjects were  challenged with a single application (02 ml, 5% solution) followed by UV-A  irradiation to a virgin area of the forearm. Minimal erythema or erythema  and/or slight oedema were seen at the irradiated sites of 26 subjects  (out of 28 completing the test). Similar findings were recorded on  untreateed irradiated patches in six subjects. At the challenge phase,  minimal erythema was noted on treated irradiated sites on 4 subjects. One  subject showed similar findings on treated non-irradiated sites and no  reactions were observed on untreated irradiated sites. Slight irritation  was seen on UV-A and UV-B irradiation of treated skin during the induction  phase but Agent AT-1269 did not induce photoallergy in humans under the  conditions of the test.  The mutagenicity of a 20% solution of Agent AT-1269 was tested in Ames  strains TA1535, TA1538, TA98, and TA100 with and without metabolic  activation provided by the addition of rat liver S9. Negative and positive  controls gave the expected responses. No induced mutants were observed at  material concentrations of up to 1 mg per plate.  A 20% solution of Agent AT-1269 was given by gavage at 0, 500, 2500 and  5000 mg/kg body weight to 10 ICR mice.  Animals were killed at 24, 48 and 72 hours for extraction of bone marrow.  No significant induction of micronucleii in bone marrow polychromatic  erythrocytes was seen.  This material contains a substantial amount of polymer considered to be of low concern. These are classified under having MWs of between 1000 to 10000 with less than 25% of molecules with MWS under 1000 and less than 10% under 500; or having a molecular weight average of over 10000. Functional groups contained on the polymer are then classified into risk categories. Being classified as a polymer of "low concern" does not mean that there are no hazards associated with the chemical.